115 related articles for article (PubMed ID: 8649545)
21. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
24. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N
Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
[TBL] [Abstract][Full Text] [Related]
25. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W
Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
28. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma.
Iwasaki Y; Ohsugi S; Takemura Y; Nagata K; Harada H; Nakagawa M
Chest; 2002 Dec; 122(6):2249-52. PubMed ID: 12475873
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
30. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
31. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
32. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Magrath I; Adde M; Shad A; Venzon D; Seibel N; Gootenberg J; Neely J; Arndt C; Nieder M; Jaffe E; Wittes RA; Horak ID
J Clin Oncol; 1996 Mar; 14(3):925-34. PubMed ID: 8622041
[TBL] [Abstract][Full Text] [Related]
33. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
34. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
35. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
[TBL] [Abstract][Full Text] [Related]
36. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
38. Primary epidural non-Hodgkin lymphoma: spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma.
Mora J; Wollner N
Med Pediatr Oncol; 1999 Feb; 32(2):102-5. PubMed ID: 9950197
[TBL] [Abstract][Full Text] [Related]
39. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
40. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.
Weintraub M; Adde MA; Venzon DJ; Shad AT; Horak ID; Neely JE; Seibel NL; Gootenberg J; Arndt C; Nieder ML; Magrath IT
J Clin Oncol; 1996 Mar; 14(3):935-40. PubMed ID: 8622042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]